[go: up one dir, main page]

Duan et al., 2020 - Google Patents

RETRACTED: Long noncoding RNA UCA1 promotes cell growth, migration, and invasion by targeting miR‐143‐3p in oral squamous cell carcinoma

Duan et al., 2020

View PDF @Full View
Document ID
11643851433138660047
Author
Duan Q
Xu M
Wu M
Zhang X
Gan M
Jiang H
Publication year
Publication venue
Cancer medicine

External Links

Snippet

Background The long noncoding RNA (lncRNA) urothelial carcinoma‐associated 1 (UCA1) is dysregulated in many types of tumors; however, its role in oral squamous cell carcinoma (OSCC) remains unclear. This study aims to determine the effect of lncRNA UCA1 on OSCC …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Similar Documents

Publication Publication Date Title
Ke et al. CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR‐4288‐induced ELF3 inhibition
Chen et al. Circ_0078767 suppresses non‐small‐cell lung cancer by protecting RASSF1A expression via sponging miR‐330‐3p
Duan et al. RETRACTED: Long noncoding RNA UCA1 promotes cell growth, migration, and invasion by targeting miR‐143‐3p in oral squamous cell carcinoma
Zhao et al. RETRACTED ARTICLE: Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer
Wang et al. MiR‐139‐5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9
Ma et al. LncRNA IGFL2‐AS1 functions as a ceRNA in regulating ARPP19 through competitive binding to miR‐802 in gastric cancer
Li et al. MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway
Li et al. Circular RNA hsa_circRNA_102209 promotes the growth and metastasis of colorectal cancer through miR‐761‐mediated Ras and Rab interactor 1 signaling
Liu et al. MicroRNA 615-3p inhibits the tumor growth and metastasis of NSCLC via inhibiting IGF2
Ni et al. miR‐92b promotes gastric cancer growth by activating the DAB2IP‐mediated PI3K/AKT signalling pathway
Wang et al. miR‐206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B
Kong et al. microRNA-372 suppresses migration and invasion by targeting p65 in human prostate cancer cells
Liu et al. Long noncoding RNA HCG18 up‐regulates the expression of WIPF1 and YAP/TAZ by inhibiting miR‐141‐3p in gastric cancer
Lu et al. RETRACTED: miR-147a suppresses the metastasis of non-small-cell lung cancer by targeting CCL5
Zhao et al. MicroRNA‐133b suppresses bladder cancer malignancy by targeting TAGLN2‐mediated cell cycle
Jia-Yuan et al. miR‐375 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by suppressing PDK1
Wu et al. LncRNA LINC00115 facilitates lung cancer progression through miR‐607/ITGB1 pathway
Li et al. miR-524-5p inhibits angiogenesis through targeting WNK1 in colon cancer cells
Jiang et al. Circular RNA hsa_circ_0000658 inhibits osteosarcoma cell proliferation and migration via the miR‐1227/IRF2 axis
Tong et al. circ_100984‐miR‐432‐3p axis regulated c‐Jun/YBX‐1/β‐catenin feedback loop promotes bladder cancer progression
Wang et al. RETRACTED ARTICLE: miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma
Zhuang et al. MiR-337-3p suppresses the proliferation and metastasis of clear cell renal cell carcinoma cells via modulating Capn4
Zhang et al. The lncRNA SNHG15/miR‐18a‐5p axis promotes cell proliferation in ovarian cancer through activating Akt/mTOR signaling pathway
Yang et al. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo
Zhang et al. MicroRNA-105 inhibits human glioma cell malignancy by directly targeting SUZ12